Braze Inc. (BRZE) put on an impressive show in premarket trading, climbing roughly 14% after delivering the kind of news Wall Street loves: beating estimates and raising guidance. The customer engagement platform reported third-quarter revenue of $190.84 million, comfortably ahead of the Street's $184.08 million estimate. Even better, management bumped up its fiscal 2026 outlook for both adjusted earnings per share and sales.
The company's quarterly adjusted earnings came in at six cents per share, meeting analyst expectations. But when you beat on the top line and raise your forward guidance, investors tend to overlook an in-line earnings print. Braze shares jumped 14.2% to $35.00 in premarket action.
Of course, Braze wasn't alone in making moves before the opening bell. Here's a look at the other stocks catching attention in early trading.
The Biggest Premarket Winners
A SPAC III Acquisition Corp (ASPC) led the charge with a stunning 254.3% surge to $37.13. That's the kind of move that makes you double-check your screen.
Enveric Biosciences Inc. (ENVB) rocketed 69% higher to $10.00 after receiving some encouraging news from the U.S. Patent and Trademark Office. The Massachusetts-based biotech company got a Notice of Allowance for a patent application covering its EVM301 Series molecules, which the company is developing as potential treatments for mental health disorders. Patent approvals can be significant catalysts for biotech stocks, and this move certainly reflects that.
Biodexa Pharmaceuticals PLC-ADR (BDRX) bounced back with a 64.5% gain to $6.70 in premarket trading. This came after the stock had dropped 54% on Tuesday, so we're seeing some volatility whiplash here.
Horizon Space Acquisition I Corp (HSPO) added 51.4% to reach $26.50, extending Tuesday's 42% gain. Whatever's driving this SPAC is clearly generating sustained interest.
ESH Acquisition Corp (ESHA) climbed 32.8% to $15.55 in early trading.
Greenwave Technology Solutions Inc. (GWAV) rose 24.3% to $8.86, recovering after a 4% decline on Tuesday.
Briacell Therapeutics Corp (BCTX) shares jumped 20% to $14.73 before the opening bell.
Destiny Tech100 Inc. (DXYZ) gained 10.5% to $30.75 in premarket activity.
GE Vernova Inc. (GEV) surged 7.7% to $673.55 after delivering a one-two punch of good news: the company doubled its dividend and raised its multi-year outlook. That's exactly the kind of shareholder-friendly announcement that gets investors excited.
The Premarket Decliners
Aimei Health Technology Co Ltd (AFJK) crashed 48.1% to $46.00, giving back a chunk of Tuesday's absolutely wild 1,006.25% surge. When you see moves like that, a significant pullback the next day is almost inevitable as traders take profits.
Lion Group Holding Ltd - ADR (LGHL) declined 36.2% to $5.14 after jumping 86% on Tuesday. The company recently announced a $10 million private placement to fund its Bitcoin acquisition, but the initial enthusiasm appears to be cooling off rapidly.
JX Luxventure Group Inc. (JXG) fell 35.6% to $5.56 in premarket trading, also reversing course after a 68% gain on Tuesday.
Immuron Ltd - ADR (IMRN) dropped 29.2% to $1.07 in early trading.
PomDoctor Ltd (POM) declined 27.1% to $3.95 before the bell.
Mind Technology Inc. (MIND) shares dipped 24.2% to $8.05 after the company reported third-quarter financial results that missed Wall Street's expectations. Disappointing earnings tend to get punished quickly in premarket trading.
Autozi Internet Technology (Global) Ltd (AZI) fell 23.8% to $0.043 after announcing a 50-for-1 share consolidation. Reverse splits are often viewed negatively by investors, who see them as a sign of distress.
Lakeland Industries Inc. (LAKE) dipped 22.7% to $11.60 following a double whammy of bad news: the company reported worse-than-expected third-quarter results and withdrew its fiscal 2026 guidance entirely. When management pulls guidance, it signals significant uncertainty about the path forward.
Cracker Barrel Old Country Store Inc. (CBRL) dropped 8.3% to $24.76 after reporting first-quarter results that disappointed analysts and cutting its fiscal 2026 sales guidance below estimates. The restaurant chain continues to face challenges in a difficult operating environment.
Denali Therapeutics Inc. (DNLI) fell 8.2% to $18.05 after announcing the pricing of a public offering of common stock and pre-funded warrants. Dilution concerns often weigh on biotech stocks when new offerings are announced.
